Ask AI

GPRC5D-Directed Bispecific Antibody Therapy in RRMM: Clinical Evidence and Practice Implications

Improve your ability to optimally integrate GPRC5D-directed bispecific antibodies into the care of patients with relapsed or refractory multiple myeloma through an expert-authored ClinicalThought commentary, podcast, and certified text module with downloadable slides.

Share

Program Content

Activities

GPRC5D BsAbs in MM
Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Podcast
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson